tirzepatide vs semaglutide for fat loss Tirzepatide and Injectable Semaglutide Correlated

Current UK guidance is unequivocal: these medications should not be used whilst breastfeeding due to insufficient human safety data and unknown effects on nursing infants

Smith, Neuropathology of the oesophagus in diabetes mellitus

Each 0.1 mL (10 units on an insulin syringe ) contains 500 mcg

This means oral exposure through nursing carries substantially lower bioavailability than injection in an adult

The results demonstrated that subcutaneous tirzepatide was the most cost-effective option for adults with obesity without diabetes, being cost-effective at a WTP threshold of $150,000 per QALY gained compared with oral semaglutide and dominating over both subcutaneous liraglutide and subcutaneous semaglutide over a 68-week time window

Personal risk tolerance regarding this regulatory ambiguity varies